For an otherwise healthy individual, what would be your front line choice for de novo Richter’s transformation?

The management of de novo transformation of CLL to DLBCL is challenging. For young fit patients, the standard of care remains RCHOP chemoimmunotherapy. Limited data exist exploring other options, including retrospective data sets and small prospective studies, but nothing published convincingly esta...